Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Tango Therapeutics (TNGX) EBIT: 2020-2025

Historic EBIT for Tango Therapeutics (TNGX) over the last 6 years, with Sep 2025 value amounting to $14.1 million.

  • Tango Therapeutics' EBIT rose 142.80% to $14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$110.3 million, marking a year-over-year increase of 21.02%. This contributed to the annual value of -$145.6 million for FY2024, which is 27.52% down from last year.
  • Tango Therapeutics' EBIT amounted to $14.1 million in Q3 2025, which was up 134.35% from -$41.0 million recorded in Q2 2025.
  • Tango Therapeutics' 5-year EBIT high stood at $14.1 million for Q3 2025, and its period low was -$42.5 million during Q1 2025.
  • For the 3-year period, Tango Therapeutics' EBIT averaged around -$29.9 million, with its median value being -$32.9 million (2024).
  • As far as peak fluctuations go, Tango Therapeutics' EBIT crashed by 965,154.24% in 2021, and later soared by 142.80% in 2025.
  • Over the past 5 years, Tango Therapeutics' EBIT (Quarterly) stood at -$22.0 million in 2021, then plummeted by 39.04% to -$30.6 million in 2022, then declined by 14.55% to -$35.0 million in 2023, then decreased by 16.84% to -$40.9 million in 2024, then spiked by 142.80% to $14.1 million in 2025.
  • Its last three reported values are $14.1 million in Q3 2025, -$41.0 million for Q2 2025, and -$42.5 million during Q1 2025.